Borealis Biosciences has secured a $30 million Series A extension led by Westlake BioPartners, bringing its total committed capital to $180 million, and appointed Christian Hordo as CEO to advance its RNA therapeutics for kidney disease.

Target Information

Borealis Biosciences is a pioneering company focused on developing next-generation RNA medicines, specifically targeting unmet medical needs in kidney disease. Established with the belief that recent scientific advancements can transform RNA therapeutics, Borealis aims to leverage these breakthroughs to improve patient outcomes. As of December 2024, the company has successfully completed an extension of its Series A funding, bringing its total capital commitment to $180 million, primarily supported by esteemed investors such as Versant Ventures, Novartis AG, and Westlake BioPartners.

Recently, Borealis appointed Christian Hordo as its Chief Executive Officer. Hordo brings a wealth of experience from his previous roles, including executive positions at Sana Biotechnology and Juno Therapeutics. The company also expanded its board with three new members: David Allison, Ph.D., Tom Frohlich, and Catherine Thut, Ph.D., thereby enhancing its governance and strategic oversight.

Industry Overview in Canada

The biotechnology sector in Canada is rapidly evolving, with a particular emphasis on innovation and research. Canada has emerged as a hub for biotech development, fueled by robust research institutions, strong government sup